强生COVID-19疫苗JNJ-78436735在早期测试中具有“高度免疫原性”

2020-09-26 Allan MedSci原创

中期分析数据表明,单剂JNJ-78436735几乎能够在所有参与者中引起强烈的中和性抗体反应。

强生公司的实验性COVID-19疫苗JNJ-78436735的I / IIa期研究结果已经出炉,研究人员称单剂量JNJ-78436735具有良好的耐受性和高度免疫原性。早期数据的发布是在强生公司最近宣布将疫苗推进到一项III期研究中之后进行的,该研究的目标对象是6万名志愿者,以测试单剂量方案。

该公司表示,它还计划在今年晚些时候对JNJ-78436735的两剂方案与安慰剂进行平行III期试验。强生公司表示:“中期分析数据表明,单剂JNJ-78436735几乎能够在所有参与者中引起强烈的中和性抗体反应。在各个年龄段患者中,包括老年人,免疫反应均相似”。

强生公司于7月底启动了JNJ-78436735的I / IIa期安慰剂对照研究。JNJ-78436735是一种表达SARS-CoV-2刺突蛋白的非复制型腺病毒载体,每次接种的剂量水平为5x1010 vp或1x1011 vp。

 

原始出处:

https://www.firstwordpharma.com/node/1760579?tsid=4

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1271738, encodeId=059c12e173899, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50175, encryptionId=2c6c501e578, topicName=强生)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Mon Sep 28 01:52:49 CST 2020, time=2020-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1393814, encodeId=172f13938148c, content=<a href='/topic/show?id=718528982e3' target=_blank style='color:#2F92EE;'>#免疫原性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28982, encryptionId=718528982e3, topicName=免疫原性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Mon Sep 28 01:52:49 CST 2020, time=2020-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888640, encodeId=cfa0888640ad, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Sun Sep 27 07:59:38 CST 2020, time=2020-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888499, encodeId=979d88849957, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210610/92eb00ec17a74ad287fe3722e1a98e59/435f291e2ec64f6599cf70b09f151f07.jpg, createdBy=f7522567113, createdName=12575f85m66暂无昵称, createdTime=Sat Sep 26 11:09:54 CST 2020, time=2020-09-26, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1271738, encodeId=059c12e173899, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50175, encryptionId=2c6c501e578, topicName=强生)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Mon Sep 28 01:52:49 CST 2020, time=2020-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1393814, encodeId=172f13938148c, content=<a href='/topic/show?id=718528982e3' target=_blank style='color:#2F92EE;'>#免疫原性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28982, encryptionId=718528982e3, topicName=免疫原性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Mon Sep 28 01:52:49 CST 2020, time=2020-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888640, encodeId=cfa0888640ad, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Sun Sep 27 07:59:38 CST 2020, time=2020-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888499, encodeId=979d88849957, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210610/92eb00ec17a74ad287fe3722e1a98e59/435f291e2ec64f6599cf70b09f151f07.jpg, createdBy=f7522567113, createdName=12575f85m66暂无昵称, createdTime=Sat Sep 26 11:09:54 CST 2020, time=2020-09-26, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1271738, encodeId=059c12e173899, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50175, encryptionId=2c6c501e578, topicName=强生)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Mon Sep 28 01:52:49 CST 2020, time=2020-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1393814, encodeId=172f13938148c, content=<a href='/topic/show?id=718528982e3' target=_blank style='color:#2F92EE;'>#免疫原性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28982, encryptionId=718528982e3, topicName=免疫原性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Mon Sep 28 01:52:49 CST 2020, time=2020-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888640, encodeId=cfa0888640ad, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Sun Sep 27 07:59:38 CST 2020, time=2020-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888499, encodeId=979d88849957, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210610/92eb00ec17a74ad287fe3722e1a98e59/435f291e2ec64f6599cf70b09f151f07.jpg, createdBy=f7522567113, createdName=12575f85m66暂无昵称, createdTime=Sat Sep 26 11:09:54 CST 2020, time=2020-09-26, status=1, ipAttribution=)]
    2020-09-27 14818eb4m67暂无昵称

    学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1271738, encodeId=059c12e173899, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50175, encryptionId=2c6c501e578, topicName=强生)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Mon Sep 28 01:52:49 CST 2020, time=2020-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1393814, encodeId=172f13938148c, content=<a href='/topic/show?id=718528982e3' target=_blank style='color:#2F92EE;'>#免疫原性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28982, encryptionId=718528982e3, topicName=免疫原性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Mon Sep 28 01:52:49 CST 2020, time=2020-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888640, encodeId=cfa0888640ad, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Sun Sep 27 07:59:38 CST 2020, time=2020-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888499, encodeId=979d88849957, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210610/92eb00ec17a74ad287fe3722e1a98e59/435f291e2ec64f6599cf70b09f151f07.jpg, createdBy=f7522567113, createdName=12575f85m66暂无昵称, createdTime=Sat Sep 26 11:09:54 CST 2020, time=2020-09-26, status=1, ipAttribution=)]
    2020-09-26 12575f85m66暂无昵称

    henhao

    0

相关资讯

COVID-19疫苗BNT162b2进入II / III期临床研究

辉瑞公司及其合作伙伴BioNTech近日表示,他们已决定将经过核苷修饰的mRNA疫苗候选产品BNT162b2推进到II / III期临床试验。

默克携两款候选疫苗加入COVID-19疫苗竞赛

默克公司(Merck&Co.)近日宣布,以未公开的价格收购Themis Bioscience,从而获得后者的COVID-19实验性候选疫苗。

英国正在提高COVID-19疫苗的生产能力

英国政府已与生物技术组织Wockhardt签署了一项为期18个月的新协议,以提高COVID-19疫苗的生产能力。根据英国政府昨天发布的一份声明,COVID-19疫苗的制造预计将于2020年9月开始。

Moderna确认与日本就实验性疫苗COVID-19疫苗供应进行会谈

Moderna近日表示,正在与日本政府商讨一项潜在的预先购买协议,日本政府将购买4000万或更多剂量的实验性COVID-19疫苗(mRNA-1273)。

伦敦帝国理工学院的实验性COVID-19疫苗:已开始人体测试,并将放弃特许权使用费

伦敦帝国理工学院的实验性COVID-19疫苗已在伦敦西部的一家机构中输注给了第一位健康志愿者。

印度血清研究所(SII)将生产阿斯利康和Novavax的COVID-19疫苗

印度血清研究所(SII)表示,它将从阿斯利康和Novavax获得授权以生产COVID-19疫苗。

拓展阅读

JNCI | COVID-19疫苗接种、感染和症状情况分析:美国癌症幸存者研究

该研究旨在全面了解美国癌症幸存者在新冠疫情期间的疫苗接种、感染和症状情况,癌症幸存者一旦感染COVID-19,更易出现中重度症状,需要针对这一脆弱人群制定COVID-19的预防和控制策略。

CGH:炎症性肠病患者接种COVID-19疫苗的长期效果和持久性

接种COVID-19疫苗可为绝大多数炎症性肠病成人患者(包括皮质类固醇使用者和老年人等脆弱人群)产生有效和持久的保护性反应。IBD患者可从COVID-19加强疫苗接种中获益。

AJOG:接种新冠肺炎疫苗后,更要警惕绝经后出血?

COVID-19疫苗的使用与新发绝经后出血诊断率增加无关。在接受COVID-19疫苗接种后的60天内,诊断为绝经后出血的情况很少见。

Journal of Hepatology:肝病患者和肝移植受者接种COVID-19疫苗后的免疫应答和临床结局

接种3种COVID-19疫苗后,肝病患者通常会对疫苗产生强大的抗体和T细胞应答,并表现为轻型COVID-19。然而,LTR持续无/低抗体滴度,似乎最易发生严重疾病。

Am J Obstet Gynecol:COVID-19疫苗接种妇女死产和早产的减少——一项关于疫苗接种和围产期结局的多中心队列研究

本研究表明妊娠期间接种COVID-19疫苗与死产和早产的减少有关,且与胎儿生长或发育的任何不利影响无关。

J Hosp Infect:最后一次接种COVID-19疫苗的时间和完全(加强)接种的医护人员中SARS-CoV-2突破感染的时间

接种疫苗的个人可以发展严重急性呼吸综合征冠状病毒-2(新型冠状病毒)突破性感染,也可以传播病毒。